Patents Issued in April 28, 2020
  • Patent number: 10632081
    Abstract: Disclosed is an intralymphatic delivery method for treating lymphatic cancer using hyaluronan nanoparticles. These nanoparticles include a hyaluronic acid derivative and a platinum compound. The hyaluronan derivative includes hyaluronic acid, modified histidine and optionally one or more of a polymer or a C4-C20 alkyl. The hyaluronic acid derivative may include linking group(s) that connect the polymer or the C4-C20 alkyl to the hyaluronic acid. The platinum compound includes dichloro(1,2-diaminocyclohexane) platinum (DACHPt), cisplatin and oxaliplatin. This intralymphatic delivery method offers significant advantages for the use of platinum medicines in treating lymphatic cancer.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: April 28, 2020
    Assignee: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Chih-Peng Liu, Ya-Chin Lo, Ming-Cheng Wei, Maggie Lu, Shuen-Hsiang Chou, Shih-Ta Chen, Hsiang-Wen Tseng
  • Patent number: 10632082
    Abstract: The present invention is directed to a process for manufacturing a transdermal delivery device comprising a backing layer, a release liner, and an adhesive layer between the backing layer and release liner. More specifically, the invention is directed to a process of preparing an adhesive layer, wherein the adhesive layer is comprised of polyisobutylene and an active pharmaceutical ingredient.
    Type: Grant
    Filed: July 19, 2010
    Date of Patent: April 28, 2020
    Assignee: Mylan Inc.
    Inventors: Russell Adam Baird, Brad L. Barnett, Russell D. Beste
  • Patent number: 10632083
    Abstract: Provided herein is an ophthalmic composition including a therapeutic active agent and an anti-inflammatory agent, in which the active agent is at least about 0.01% w/v of chlorhexidine, derivatives, or analogues of chlorhexidine, or a pharmaceutically acceptable salt, solvent, hydrate, or polymorph thereof. Methods for treating or preventing ocular disease or infection in a subject in need thereof are also provided. The method may include administering to an eye of a subject an ophthalmic composition including chlorhexidine, derivatives, or analogues of chlorhexidine, or a pharmaceutically acceptable salt, solvent, hydrate, or polymorph thereof, and an anti-inflammatory agent. The chlorhexidine, derivatives, or analogues of chlorhexidine, or a pharmaceutically acceptable salt, solvent, hydrate, or polymorph thereof and the anti-inflammatory agent are present in an amount effective to treat or prevent the ocular disease or infection in a subject in need thereof.
    Type: Grant
    Filed: January 24, 2018
    Date of Patent: April 28, 2020
    Assignee: SaCSh Corp.
    Inventor: Uri Shabto
  • Patent number: 10632084
    Abstract: An aquaporin 4 function promotor contains a compound represented by Formula (1) or (2) or a pharmaceutically acceptable salt thereof, as an active ingredient. (In the formula, n11 represents an integer of 1 to 10, and R21 represents one selected from the group consisting of an alkyl group having 1 to 10 carbon atoms, an alicyclic heterocyclic group, an aromatic hydrocarbon group, and an aromatic heterocyclic group.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: April 28, 2020
    Assignee: NIIGATA UNIVERSITY
    Inventors: Tsutomu Nakada, Vincent Huber, Hironaka Igarashi, Yuji Suzuki, Ingrid Kwee
  • Patent number: 10632085
    Abstract: Processes for the preparation of 2,5-dihydroxybenzenesulfonic acid salts of formula (I) and a crystalline form of potassium 2,5-dihydroxybenzenesulfonic acid are provided. Also provided are methods of treating psoriasis comprising administering crystalline forms of potassium 2,5-dihydroxybenzenesulfonic acid.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: April 28, 2020
    Assignee: AmDerma Pharmaceuticals, LLC
    Inventors: Unni Santhosh, Annadurai Marimuthu Senthilkumar, Bodireddy Mohan Reddy, Rajendran Kamala, Mahender Rao Siripragada
  • Patent number: 10632086
    Abstract: In various embodiments, methods and compositions for treating Raynaud's disease and Raynaud's phenomenon are provided. Topical administration of a semisolid composition comprising a prostaglandin E1 compound provides the desired relief of the Raynaud's disease or Raynaud's phenomenon without the possible complications of systemic administration. The semisolid composition can be administered as needed, or in a regimen of several doses per day.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: April 28, 2020
    Assignee: NEXMED HOLDINGS, INC.
    Inventors: Daniel W. Frank, Richard Martin, Bassam B. Damaj
  • Patent number: 10632087
    Abstract: The present invention relates to pharmaceutical compositions comprising a combination of a therapeutically-effective amount of the antiviral compound famciclovir and a therapeutically-effective amount of the COX-2 inhibitor meloxicam. The invention is further related to methods of treating functional somatic syndromes by administering a therapeutically-effective combination of famciclovir and meloxicam.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: April 28, 2020
    Assignee: INNOVATIVE MED CONCEPTS, LLC.
    Inventor: William L. Pridgen
  • Patent number: 10632088
    Abstract: Disclosed are methods, compounds, and compositions for treating infection by an Apicomplexan parasite that include administering a compound that selectively inactivates ornithine aminotransferase of the Apicomplexan parasite. Specifically, the methods, compounds, compounds may be utilized for treating infection by Toxoplasma gondii and toxoplasmosis and for treating infection by Plasmodium falciparum and malaria. The compounds disclosed herein are observed to selectively inactivate Toxoplasma gondii ornithine aminotransferase (TgOAT) relative to human OAT and relative to human ?-aminobutyric aminotransferase (GABA-AT).
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: April 28, 2020
    Assignee: Northwestern University
    Inventors: Richard B. Silverman, Hoang V. Le, Rima L. McLeod, Dustin D. Hawker
  • Patent number: 10632089
    Abstract: A tyrosinase activity inhibitor is prepared by combining (A) a metal (zinc, cobalt or iron) chelate compound of ?-lipoyl amino acid or its pharmaceutically acceptable salt with (B-1) a human manganese SOD or (B-2) an ascorbic acid compound such as ascorbic acid and ascorbyl glucoside. A ratio (R1) of the (B-1) component content to the (A) component content is preferably 0.001 to 1,500, when R1 is defined as R1=[Unit concentration of (B-1) component (unit/mL)/Concentration of (A) component (?g/mL)], and a ratio (R2) of the (A) component content to the (B-2) component content is preferably 0.0001 to 1,000, when R2 is defined as R2=[Concentration of (A) component (m/mL)/Concentration of (B-1) component (mg/mL)]. An external preparation for skin contains the (A) component and the (B-1) component or the (B-2) component as effective ingredients for inhibiting tyrosinase activity.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: April 28, 2020
    Assignee: JO Cosmetics Co., Ltd.
    Inventors: Kanako Wada, Katsura Adachi
  • Patent number: 10632090
    Abstract: Methods of suppressing cyclooxygenase activity or reducing platelet aggregation of a mammal in need thereof by administering to a mammal in need thereof an effective amount of trans-resveratrol and arginine for a period of at least two weeks.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: April 28, 2020
    Inventors: Shil Kothari, Gary Troxel
  • Patent number: 10632091
    Abstract: Compositions of L-4-chlorokynurenine are provided, as are methods for the treatment of neurologica dyslinction.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: April 28, 2020
    Assignee: VISTAGEN THERAPEUTICS, INC.
    Inventors: H. Ralph Snodgrass, Allen E. Cato, Jack S. Hicklin
  • Patent number: 10632092
    Abstract: The invention provides methods and compositions for reducing the percentage of body fat in an animal or human and increasing the level of adiponectin in an animal or human. Such methods include administering to an animal or human sufficient levels of a compound comprising a tri blend of HPMC (K15, K100, and K200) and myristic fatty acid.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: April 28, 2020
    Assignee: First Fruits Business Ministry, LLC
    Inventors: Roger J. Catarino, William D. Kuhne
  • Patent number: 10632093
    Abstract: The invention pertains to the use of a composition in the manufacture of a product or method for therapeutically improving, promoting, restoring or maintaining recognition and/or working memory in a subject suffering from PKU and/or in a subject suffering from or at increased risk of impaired recognition and/or working memory associated with PKU, said composition comprising therapeutic amounts of: (i) at least one ?-3 polyunsaturated fatty acid (LCPUFA) selected from the group consisting of docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA) and docosapentaenoic acid (DPA); (ii) choline, a choline salt and/or choline ester; and (iii) at least one B vitamin selected from the group consisting of vitamin B6, vitamin B12 and vitamin B9, including functional equivalents thereof, preferably vitamin B6 and/or vitamin B12, and functional equivalents thereof. The invention also pertains to a composition for use in such use or method.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: April 28, 2020
    Assignee: N.V. NUTRICIA
    Inventors: Mattheus Cornelis De Wilde, Danielle Stefanie Counotte
  • Patent number: 10632094
    Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: April 28, 2020
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni
  • Patent number: 10632095
    Abstract: The invention describes a long-acting veterinary composition comprising at least one ketoprofen ester prodrug. The composition also comprises at least one veterinary acceptable triglyceride, and optionally, at least one preservative, and optionally, at least one additional veterinary acceptable excipient. The invention also describes a method of treating an animal for fever, pain, and/or inflammation by administering the long-acting composition comprising at least one ketoprofen ester prodrug to the animal in need thereof.
    Type: Grant
    Filed: December 15, 2014
    Date of Patent: April 28, 2020
    Assignee: Zoetis Services LLC
    Inventors: Richard Andrew Ewin, Steven X. Hu, Susan M. Machkovech, Barton H. Manning, Stephen Lee Secreast
  • Patent number: 10632096
    Abstract: A method of quenching excited state energy from a photodegradable pigment that has been excited by absorption of light having a wavelength in the wavelength range of 290-800 nm, comprising reacting a pigment with a conjugated fused tricyclic compound having electron withdrawing groups of Formula (II) or a salt thereof: wherein: A is selected from the group consisting of O, S, C?O, C?S, B1, B2, D1 and D2 are each independently selected from the group consisting of F, Cl, Br, I, CF3, CC13, NR33+, NO2, CN, C(?O)R4, C(?O)OR?, SO2R5, aryl, and —C?CHR6; each m independently is 0, 1, 2, 3, or 4; a is 0 or 1; each R? is independently selected from the group consisting of LI, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, and aryl; R2 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, and aryl; each R3 is independently selected from the group consisting of H and C1-C6 alkyl; each R4 is independently selected from the group consisting of H, alkyl, alkenyl, alkynyl,
    Type: Grant
    Filed: January 15, 2018
    Date of Patent: April 28, 2020
    Assignee: Hallstar Beauty and Personal Care Innovations Company
    Inventors: Craig A. Bonda, Shengkui Hu
  • Patent number: 10632097
    Abstract: The present patent application relates to a novel organometallic compound, a process for the preparation thereof, and its use.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: April 28, 2020
    Assignee: Umicore AG & Co. KG
    Inventors: Eileen Woerner, Ralf Karch, Andreas Rivas-Nass, Angelino Doppiu, Annika Frey
  • Patent number: 10632098
    Abstract: The present invention provides a cannabis-based flavonoid pharmaceutical composition including any one or more selected from the group of Apigenin, Cannflavin A, Cannflavin B, Cannflavin C, Chiysoeriol, Cosmosiin and Flavocannabiside or their synthases, for the prevention and treatment of certain ocular diseases and related disorders.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: April 28, 2020
    Inventors: Henry I C Lowe, Ngeh J. Toyang
  • Patent number: 10632099
    Abstract: This disclosure is directed to non-aromatic difluoro analogues of resorcylic acid lactones, pharmaceutical compositions comprising non-aromatic difluoro analogues of resorcylic acid lactones, and methods of treatment comprising non-aromatic difluoro analogues of resorcylic acid lactones.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: April 28, 2020
    Assignee: University of North Carolina at Greensboro
    Inventors: Mitchell P. Croatt, Lara Fakhouri, Nicholas H. Oberlies, Cedric Pearce
  • Patent number: 10632100
    Abstract: Disclosed is application of obacunone in the manufacture of a medicament for prevention or treatment of lung injury and pulmonary fibrosis. The medicament consists of obacunone and pharmaceutically acceptable auxiliaries and additives, wherein obacunone is 3% to 25% by mass in the medicament. The obacunone in the medicament can inhibit bleomycin-induced lung injury and pulmonary fibrosis in mice, and regulate the expression of the inflammation-associated cytokines in the bleomycin-induced injured lung tissue in mice.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: April 28, 2020
    Assignee: GUANGDONG PROVINCIAL HOSPITAL OF TRADITIONAL CHINESE MEDICINE
    Inventors: Yang Xu, Shengmei Xu, Weimin Chen
  • Patent number: 10632101
    Abstract: A composition for supporting endogenous systems related to life span, inhibiting mTOR, and reducing damage associated with oxidative phosphorylation. The composition comprises an upregulating compound mixture configured to upregulate an endogenous antioxidant system, an exogenous antioxidant mixture configured to inhibit oxidation of biomolecules by reactive oxygen species, and a mineral mixture configured to provide one or more cofactors to a endogenous antioxidant enzyme. The endogenous antioxidant system includes regulation of mitophagy through mTOR mediated regulation, and a Nrf2 transcription factors that promotes transcription of antioxidant genes.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: April 28, 2020
    Assignee: USANA Health Sciences, Inc.
    Inventors: Mark Brown, John Cuomo, Jeremy Tian
  • Patent number: 10632102
    Abstract: The invention provides carbazole derivatives for the treatment of fibrotic diseases (pathological collagen deposition) in tissues and organs, and related symptoms, and conditions thereof.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: April 28, 2020
    Assignee: RAZIEL THERAPEUTICS LTD
    Inventor: Shmuel Ben-Sasson
  • Patent number: 10632103
    Abstract: Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: April 28, 2020
    Assignee: Epizyme, Inc.
    Inventors: Richard Chesworth, Lorna Helen Mitchell, Gideon Shapiro
  • Patent number: 10632104
    Abstract: Described herein are methods and compositions for the treatment of conditions, diseases, or disorders associated with autotaxin activity. The methods and compositions disclosed herein include the use of at least one autotaxin inhibitor compound.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: April 28, 2020
    Assignee: SABRE THERAPEUTICS LLC
    Inventors: Gretchen Bain, Jillian Frances Evans, John Howard Hutchinson, David Lonergan
  • Patent number: 10632105
    Abstract: The invention relates to the selective targeting of specific ?2 adrenergic receptor subtypes for facilitating and also restoring standing and walking in a subject affected by spinal cord disorders, in particular spinal cord injury. In particular, the improvement of locomotion by targeting specific receptor subtypes can be achieved by stimulation of the ?2c receptor subtype using an ?2c specific agonist or by blocking the ?2a receptor subtype using ?2a antagonists. A combination of an ?2c agonist and an ?2a antagonist is also provided for a synergistic effect. Alternatively, a large ?2 agonist can be used in combination with an ?2a antagonist to achieve specific stimulation of the ?2c receptor. Pharmaceutical compositions, kit-of-parts and therapeutic systems comprising said agonists/antagonists as active agents are objects of the present invention.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: April 28, 2020
    Assignee: ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL)
    Inventors: Grégoire Courtine, Quentin Barraud, Pavel Musienko
  • Patent number: 10632106
    Abstract: Provided herein are methods of cancer treatment by administering an effective amount of an endogenous ligand for the aryl hydrocarbon (Ah) receptor (AhR) named ITE or one of its structural analogs to a patient with cancer, for example, prostate, liver, lung, ovarian, breast, skin, colon (or rectum), stomach, pancreatic, kidney, bladder, soft tissue, or cervical cancer.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: April 28, 2020
    Assignee: Ariagen, Inc.
    Inventor: Jiasheng Song
  • Patent number: 10632107
    Abstract: The present invention provides crystalline forms of Deutetrabenazine. Specific crystalline forms provided by the present invention include Deutetrabenazine Form APO-I, a co-crystal of Deutetrabenazine and quercetin, and Deutetrabenazine Form APO-II, a co-crystal of Deutetrabenazine and luteolin. Also provided are pharmaceutical compositions including the Deutetrabenazine crystalline forms, and the use of these forms in the treatment of tardive dyskinesia and chorea associated with Huntington's disease.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: April 28, 2020
    Assignee: Apotex Inc.
    Inventors: Fabio E. S. Souza, Bahareh Khalili, Allan W. Rey
  • Patent number: 10632108
    Abstract: The present invention relates to a sterile pharmaceutical composition comprising tiotropium or a pharmaceutically acceptable salt thereof, for inhalation via nebulization to a subject (e.g. a human). The invention also relates to a process for preparing the pharmaceutical composition and its use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) in a subject.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: April 28, 2020
    Assignee: GLENMARK SPECIALTY S.A.
    Inventors: Ulhas R. Dhuppad, Franciscus Koppenhagen, Sunil Chaudhari, Suresh Rajurkar, Chandrakant Dhatrak, Alkesh Kasliwal
  • Patent number: 10632109
    Abstract: The present invention relates to a sterile pharmaceutical composition comprising tiotropium or a pharmaceutically acceptable salt thereof, for inhalation via nebulization to a subject (e.g. a human). The invention also relates to a process for preparing the pharmaceutical composition and its use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) in a subject.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: April 28, 2020
    Assignee: GLENMARK SPECIALTY S.A.
    Inventors: Ulhas R. Dhuppad, Franciscus Koppenhagen, Sunil Chaudhari, Suresh Rajurkar, Chandrakant Dhatrak, Alkesh Kasliwal
  • Patent number: 10632110
    Abstract: Provided are a pharmaceutical composition for preventing or treating cancer and a method of preventing or treating cancer using the same. Cancer may be effectively prevented or treated using the pharmaceutical composition and method.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: April 28, 2020
    Assignee: MEDPACTO INC.
    Inventors: Il Ho Ha, Seong Jin Kim
  • Patent number: 10632111
    Abstract: The present invention relates to a donepezil derivative of general formula (I) or a pharmaceutically acceptable salt thereof, wherein R in the formula is as disclosed herein; and a method for preparation thereof; and a composition comprising an effective amount of a compound of the general formula (I) or a pharmaceutically acceptable salt thereof. The present invention also relates to use of a compound of the general formula (I) or a pharmaceutically acceptable salt thereof in preparing a medicament for treating a disease resulted from an abnormality in acetylcholinesterase activity.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: April 28, 2020
    Assignee: NANJING NORATECH PHARMACEUTICALS CO., LTD.
    Inventors: Fei Liu, Cuixia Zhang, Chenggang Lin, Chunyan Zhou, Pan Chen, Wei Wang, Lulu Wang
  • Patent number: 10632112
    Abstract: Provided herein is a combination therapy comprising a compound of Formula I and peginterferon alfa-2a, or another interferon analog. The combination therapy is useful for the treatment of HBV infection. Also provided herein are compositions comprising a compound of Formula I and peginterferon alfa-2a, or another interferon analog.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: April 28, 2020
    Assignee: NOVIRA THERAPEUTICS, INC.
    Inventor: George D. Hartman
  • Patent number: 10632113
    Abstract: Disclosed are solid oral pharmaceutical compositions that that are intended to provide protection against overdose and tampering, as well as abuse deterrence. The compositions contain a plurality of granules or multi-particulates. A first population of multi particulates contains an API or drug susceptible to abuse, a polymer matrix, and an outer coating that contains a cationic pH dependent polymer. These multi particulates also contain a plasticizer and a surfactant. A second population of multi particulates contains a viscosity building polymer and an alkaline buffering agent. Compositions may further include a disintegrant, and/or additional viscosity building polymers and/or alkaline buffering agents and/or ion exchange polymers. Also disclosed are the methods of making and using the compositions.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: April 28, 2020
    Assignee: KASHIV BIOSCIENCES, LLC
    Inventors: Siva Ram Kiran Vaka, Ashish Chatterji, Dipen Desai, Wantanee Phuapradit, Navnit H. Shah, Atsawin Thongsukmak, Kanji Meghpara
  • Patent number: 10632114
    Abstract: Described herein are methods for using compounds that activate pyruvate kinase.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: April 28, 2020
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Shin-San Michael Su, Lenny Dang
  • Patent number: 10632115
    Abstract: The invention discloses a use of a statin compound in the preparation of local drugs for improving lipid metabolism and treating obesity, hypertension, hyperlipidemia, fatty liver and hyperglycemia; and statin compound local compositions for improving lipid metabolism and treating obesity, hypertension, fatty liver, hyperlipidemia, atherosclerosis, coronary heart disease, apoplexy and other cardiovascular and cerebrovascular diseases, and drug formulation and preparation method thereof.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: April 28, 2020
    Assignee: Peking University Third Hospital
    Inventors: Chunli Song, Ning Yang, Yueyi Cui, Yingsheng Yu
  • Patent number: 10632116
    Abstract: The present invention relates to the use of 5-HT1 agonists in pharmaceutical compositions, compounds and methods for treatment of movement disorders related to neurological dysfunctions. The invention is particularly relevant for treatment of patients suffering from tardive dyskinesia, Parkinson's disease and associated disorders thereof. Kits of parts comprising the 5-HT1 agonist compounds or pharmaceutical compositions according to the present invention, as well as methods of preparation are also provided by the present invention.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: April 28, 2020
    Assignee: Contera Pharma A/S
    Inventors: John Bondo Hansen, Mikael S. Thomsen
  • Patent number: 10632117
    Abstract: The present invention relates to the identification of the glycogen synthase kinase-3 beta (GSK3B or GSK-3P) as a therapeutic target of pigmentation disorder and as biomarker of pigmentation status. The invention in particular relates to products and methods for treating a hypopigmentation disorder. The invention also relates to products and methods for detecting, diagnosing, staging or monitoring the course of hypopigmentation disorder and is particularly suited for human subjects.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: April 28, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITY DE NICE SOPHIA ANTIPOLIS, CHU DE NICE
    Inventors: Thierry Passeron, Florence Joly
  • Patent number: 10632118
    Abstract: The invention provides a compound of formula (Ia), and pharmaceutically acceptable salts thereof. The invention also provides use of the compounds or salts as modulators of Kv3.1 and/or Kv3.2, and in the treatment of diseases or disorders where a modulator of Kv3.1 and/or Kv3.2 is required, such as depression and mood disorders, hearing disorders, schizopherenea, substance abuse disorders, sleep disorders or epilepsy.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: April 28, 2020
    Assignee: AUTIFONY THERAPEUTICS LIMITED
    Inventors: Giuseppe Alvaro, Anne Decor, Stefano Fontana, Dieter Hamprecht, Charles Large, Agostino Marasco
  • Patent number: 10632119
    Abstract: The present invention provides a compound of formula (I) or a salt form thereof. The compound of formula (I) has ALK and FAK inhibitory activity, and may be used to treat proliferative disorders.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: April 28, 2020
    Assignee: CEPHALON, INC.
    Inventors: Shawn P. Allwein, Laurent Courvoisier, Martin J. Jacobs, Gregory R. Ott
  • Patent number: 10632120
    Abstract: The disclosure provides methods of use of certain compounds that are useful for treating certain symptoms of endocrine disturbances, and in particular those associated with hot flashes.
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: April 28, 2020
    Assignee: Emory University
    Inventors: Michael G. Natchus, Richard Arrendale, Dennis Liotta, Ketan Desai, Hyunsuk Shim
  • Patent number: 10632121
    Abstract: In certain embodiments the present invention involves methods of killing tumor cells that comprise an oncogenic PDGFR mutation, and methods of treating subjects having tumors that comprise such tumor cells. In some embodiments such methods involve using PI3K inhibitors, or a combination of a PI3K inhibitor and an mTOR inhibitor, or a dual PI3K/mTOR inhibitor. The present invention also provides methods for determining whether a subject is a candidate for treatment, methods for evaluating the efficacy of treatment, and other methods, compositions, model systems, and assays.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: April 28, 2020
    Inventors: Ingo Kai Mellinghoff, Sara Kubek
  • Patent number: 10632122
    Abstract: The present disclosure is directed to compositions and methods for inhibiting either Toxoplasma gondii (T. gondii) calcium dependent protein kinases (TgCDPKs) or Cryptosporidium parvum (C. parvum) and Cryptosporidium hominus (C. hominus) calcium dependent protein kinases (CpCDPKs) using pyrazolopyrimidine and/or imidazo[1,5-a]pyrazine inhibitors, of the Formula (I), wherein the variables X, Y, Z, R1, and R3 are defined herein.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: April 28, 2020
    Assignee: University of Washington
    Inventors: Wilhelmus G. J. Hol, Eric T. Larson, Dustin James Maly, Wesley C. Van Voorhis, Ethan Merritt, Kayode K. Ojo
  • Patent number: 10632123
    Abstract: The invention discloses compositions comprising BRaf inhibitors and uses thereof for treating and/or preventing by topical or systemic administration cutaneous conditions caused by treatment with EGFR inhibitors and/or PI3K inhibitors.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: April 28, 2020
    Assignee: Lutris Pharma Ltd.
    Inventor: Noa Shelach
  • Patent number: 10632124
    Abstract: The present disclosure teaches methods for treating and preventing a variety of neurodegenerative conditions and symptoms associated therewith, including Alzheimer's disease (AD) and idiopathic Parkinson's disease (iPD), by utilizing adrenoceptor antagonists. Adrenoceptor antagonists that can be used include ?-blockers, such as acebutolol, betaxolol, bisopropolol, bopindolol, carvedilol, metoprolol, oxprenolol, propranolol, and timolol. The present disclosure also teaches methods for diagnosing and monitoring the progression of iPD.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: April 28, 2020
    Assignee: Cedars-Sinai Medical Center
    Inventors: Michele Tagliati, Gennaro Pagano
  • Patent number: 10632125
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of autoimmune diseases and inflammatory conditions.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: April 28, 2020
    Assignee: THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING
    Inventors: Martin Scobie, Olov Wallner, Tobias Koolmeister, Karl Sven Axel Vallin, Carl Martin Henriksson, Evert Homan, Thomas Helleday, Sylvain Jacques, Roland Julius Yu Fiskesund
  • Patent number: 10632126
    Abstract: The present disclosure relates to bicyclic heterocycles of Formula (I?), and pharmaceutical compositions of the same, that are inhibitors of the FGFR3 and/or FGFR4 enzyme and are useful in the treatment of FGFR-associated diseases.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: April 28, 2020
    Assignee: Incyte Corporation
    Inventors: Alexander Sokolsky, Liangxing Wu, Wenqing Yao
  • Patent number: 10632127
    Abstract: The instant invention relates to novel conjugates of the compound of formula (I): S—L—A??(I) or salts thereof, wherein A is a ?-secretase inhibitor, L is a linker and S is a peptidase-specific substrate, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: April 28, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Johannes Aebi, Alexander Flohr, Juillerat-Jeanneret Lucienne, Golshayan Dela
  • Patent number: 10632128
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Grant
    Filed: August 22, 2019
    Date of Patent: April 28, 2020
    Assignee: AMGEN INC.
    Inventors: Paul E. Harrington, Kate Ashton, Sean P. Brown, Matthew R. Kaller, Todd J. Kohn, Brian Alan Lanman, Kexue Li, Yunxiao Li, Jonathan D. Low, Ana Elena Minatti, Alexander J. Pickrell, Markian M. Stec, Joshua Taygerly
  • Patent number: 10632129
    Abstract: This invention provides for a unit dosage form of treprostinil at a dosage of between 0.1 mg/mL and 25 mg/mL in a sterile fluid composition formulated for subcutaneous or intravenous injection, which composition does not comprise an antimicrobial preservative, and methods of reducing irritation, inflammation or a combination thereof at a site of subcutaneous or intravenous infusion of treprostinil in a subject in need thereof.
    Type: Grant
    Filed: November 15, 2015
    Date of Patent: April 28, 2020
    Assignee: SteadyMed Ltd.
    Inventors: Jonathan Rigby, Peter Noymer, Robert Zwolinski
  • Patent number: 10632130
    Abstract: A method of promoting muscle growth consisting of providing a dietary supplement containing an effective amount of dehydroandrosterol to a user. A composition for promoting muscle growth containing an effective amount of dehydroandrosterol.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: April 28, 2020
    Inventors: John Dunlop, Dongdong Chen